PP007 - ASSOCIATION OF PRE-CHEMOTHERAPY BODY COMPOSITION WITH TREATMENT-RELATED TOXICITY IN GASTROINTESTINAL CANCER: A PROSPECTIVE STUDY

PP007

ASSOCIATION OF PRE-CHEMOTHERAPY BODY COMPOSITION WITH TREATMENT-RELATED TOXICITY IN GASTROINTESTINAL CANCER: A PROSPECTIVE STUDY

A. B. Barreto¹, A. D. S. Couto¹, N. C. S. Souza^2,*, R. B. Martucci¹

¹Rio de Janeiro State University (UERJ), ²Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil

Rationale: Body composition influences treatment tolerance in cancer, but comprehensive assessments of muscle and adipose compartments in gastrointestinal cancer are limited; this study examined their independent associations with treatment-related toxicities.

Methods: Prospective cohort of adults with gastrointestinal cancer assessed before chemotherapy. Computed tomography at the L3 level was used to assess skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), subcutaneous (SAT), visceral (VAT), intermuscular (IMAT), and total adipose tissue index (TATI). Nutritional status was assessed by the Patient-Generated Subjective Global Assessment, and toxicities by the Common Terminology Criteria for Adverse Events v5. Logistic regression identified predictors of toxicity, adjusted for age, sex, tumor site, and stage.

Results: Among 90 patients, 88% had advanced disease and 61% had colorectal cancer. Neoadjuvant (38%) and palliative (33%) chemotherapy were most common. Malnutrition prevalence was 81%. All patients had at least one toxicity, mainly anemia (74%) and nausea (59%). BMI >25 kg/m² (OR=2.89; 95%CI: 1.04–8.0; p=0.04), VAT >50th percentile (OR=3.0; 95%CI: 1.14–7.86; p=0.025), and TATI >50th percentile (OR=2.82; 95%CI: 1.08–7.38; p=0.034) were associated with hepatic toxicity; TATI >50th percentile (OR=4.63; 95%CI: 1.36–15.69; p=0.014) and IMAT >50th percentile (OR=5.49; 95%CI: 1.53–19.62; p=0.009) were associated with gastrointestinal toxicity; muscle-related measures were not.

Conclusion: Excess adipose tissue, rather than muscle measures, was associated with treatment-related toxicities, supporting its role in risk stratification.

References: National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bethesda, MD: National Cancer Institute; 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. 

Disclosure of Interest: None declared